Literature DB >> 30587548

Biomarkers for Immunotherapy Toxicity: Are Cytokines the Answer?

Douglas B Johnson1, Justin M Balko2.   

Abstract

Immune checkpoint inhibitors induce durable responses in some patients with advanced cancer but may simultaneously trigger autoinflammatory immune-related adverse events (irAE). The pathogenesis of irAEs may relate to genetic predisposition, environmental insults, or tumor-host interactions. Elevated expression of certain cytokines may signal subclinical inflammation that evolves into severe irAEs with treatment.See related article by Lim et al., p. 1557. ©2018 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30587548      PMCID： PMC6397678          DOI： 10.1158/1078-0432.CCR-18-3858

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  10 in total

Review 1.  The current landscape of immunotherapy for pediatric brain tumors.

Authors:  Eugene I Hwang; Elias J Sayour; Catherine T Flores; Gerald Grant; Robert Wechsler-Reya; Lan B Hoang-Minh; Mark W Kieran; Joanne Salcido; Robert M Prins; John W Figg; Michael Platten; Kate M Candelario; Paul G Hale; Jason E Blatt; Lance S Governale; Hideho Okada; Duane A Mitchell; Ian F Pollack
Journal:  Nat Cancer       Date:  2022-01-20

Review 2.  Immune checkpoint inhibitor-related interstitial lung disease in patients with advanced non-small cell lung cancer: systematic review of characteristics, incidence, risk factors, and management.

Authors:  Seohyun Kim; Jeong Uk Lim
Journal:  J Thorac Dis       Date:  2022-05       Impact factor: 3.005

Review 3.  Potential Effect of Immunotherapy Agents on Cognitive Function in Cancer Patients.

Authors:  Florence Joly; Hélène Castel; Laure Tron; Marie Lange; Janette Vardy
Journal:  J Natl Cancer Inst       Date:  2020-02-01       Impact factor: 13.506

Review 4.  Advances on immune-related adverse events associated with immune checkpoint inhibitors.

Authors:  Yong Fan; Yan Geng; Lin Shen; Zhuoli Zhang
Journal:  Front Med       Date:  2020-08-10       Impact factor: 4.592

5.  Development and Validation of a Radiomics Nomogram Using Computed Tomography for Differentiating Immune Checkpoint Inhibitor-Related Pneumonitis From Radiation Pneumonitis for Patients With Non-Small Cell Lung Cancer.

Authors:  Qingtao Qiu; Ligang Xing; Yu Wang; Alei Feng; Qiang Wen
Journal:  Front Immunol       Date:  2022-04-26       Impact factor: 8.786

Review 6.  The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients.

Authors:  Xiaoyang Zhai; Jian Zhang; Yaru Tian; Ji Li; Wang Jing; Hongbo Guo; Hui Zhu
Journal:  Cancer Biol Med       Date:  2020-08-15       Impact factor: 4.248

7.  Prognostic significance of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for advanced non-small cell lung cancer patients with high PD-L1 tumor expression receiving pembrolizumab.

Authors:  Doran Ksienski; Elaine S Wai; Deepu Alex; Nicole S Croteau; Ashley T Freeman; Angela Chan; Tiffany Patterson; Melissa Clarkson; Leathia Fiorino; Zia Poonja; David Fenton; Sarah Irons; Mary Lesperance
Journal:  Transl Lung Cancer Res       Date:  2021-01

8.  A digital single-molecule nanopillar SERS platform for predicting and monitoring immune toxicities in immunotherapy.

Authors:  Junrong Li; Alain Wuethrich; Abu A I Sina; Han-Hao Cheng; Yuling Wang; Andreas Behren; Paul N Mainwaring; Matt Trau
Journal:  Nat Commun       Date:  2021-02-17       Impact factor: 14.919

Review 9.  Crossed Pathways for Radiation-Induced and Immunotherapy-Related Lung Injury.

Authors:  Zengfu Zhang; Jialin Zhou; Vivek Verma; Xu Liu; Meng Wu; Jinming Yu; Dawei Chen
Journal:  Front Immunol       Date:  2021-12-01       Impact factor: 7.561

10.  Safety and efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients with preexisting antinuclear antibodies: a retrospective cohort study.

Authors:  Dongming Zhang; Yuequan Shi; Xiaoyan Liu; Jia Liu; Yan Xu; Jing Zhao; Wei Zhong; Lukas Käsmann; Taiki Hakozaki; Mariano Provencio; Nobuyuki Horita; Nobuhiko Fukuda; Minjiang Chen; Mengzhao Wang
Journal:  Transl Lung Cancer Res       Date:  2022-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.